Trial of Zinc Supplements for Young Infants with Clinical Severe Infection in Tanzania
Trial of Zinc Supplements for Young Infants with Clinical Severe Infection in Tanzania
批准号:
10635077
负责人:
CHRISTOPHER P DUGGAN
金额:
$64.85万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-02-17 至 2028-01-31
关键词:
Africa South of the SaharaAgeAntibiotic ResistanceAntibiotic TherapyAntibioticsAntimicrobial ResistanceAsiaBacterial InfectionsBiologicalCase Fatality RatesCessation of lifeChestChildChild MortalityChildhoodClinicalClinical ManagementDataDeveloping CountriesDevelopmentEnrollmentEtiologyExposure toGeneticGoalsGrowthGuidelinesHealthHeterogeneityHospitalizationHospitalsIncidenceInfantInfant HealthInfant MortalityInfectionInnovative TherapyInterventionLengthLifeMagnesiumMeningitisMeta-AnalysisModificationMorbidity - disease rateMovementNorthern AfricaNutrient availabilityNutritional statusOralOutcomeParticipantPlacebosPneumoniaPoliciesPopulationProbabilityPublishingRandomizedRandomized, Controlled TrialsRecommendationRegimenReportingRiskSample SizeSepsisSeveritiesSigns and SymptomsSpecimenSustainable DevelopmentTabletsTanzaniaTemperatureTimeTreatment FailureTreatment outcomeVariantVital StatusWeightWorld Health OrganizationZinc SulfateZinc deficiencyZinc supplementationcostdisabilitydouble-blind placebo controlled trialefficacy testinghospital readmissionimprovedinnovationlow and middle-income countriesmortalityneonatal deathneonateprimary outcomerandomized trialsecondary outcomesuccesssurvival outcometreatment effect
中文摘要
项目摘要
该项目的总体目标是研究锌补充剂与标准抗生素疗法的结合。
作为一种简单、低成本且容易获得的干预措施,可提高患者的存活率和治疗结果
坦桑尼亚婴幼儿因世卫组织IMCI标准定义的“临床严重感染”而住院。相遇
为了实现这些目标,我们建议进行一项锌的随机、双盲、安慰剂对照试验
坦桑尼亚达累斯萨拉姆的补充。
简而言之,我们将招募3,250名坦桑尼亚婴儿(0-59天)因临床严重感染而住院。
坦桑尼亚的达累斯萨拉姆。所有幼儿都将接受标准的抗生素治疗,并将被随机分配到
接受14天的疗程,每天两次口服5毫克的元素锌补充剂(每天10毫克)或匹配的14-
每日两次的安慰剂疗程。参与者将接受为期90天的跟踪,以评估生命状态
和治疗结果。我们还将收集生物样本以评估潜在的作用机制。
并根据感染的病因学评估对任何治疗效果的修改。试验的主要结果是
一)90天全因死亡率和二)治疗失败(死亡的综合终点,对生命的新要求
支持或需要改用二线抗生素)。试验的次要结果包括a)时间
临床严重感染的体征和症状停止,b)出院时间,c)复发的风险
住院和d)90天内营养状况的变化,通过按年龄长短、体重长短和
按年龄计算的体重z分数。
迫切需要来自随机试验的证据作为低成本和高影响的创新来改进
坦桑尼亚和其他发展中国家需要婴儿存活才能达到儿童死亡率。
到2030年可持续发展目标(SDG)。
英文摘要
Project Summary
The overall project goal is to investigate zinc supplementation in combination with standard antibiotic therapy
as a simple, low-cost, and readily available intervention to improve survival and treatment outcomes for
Tanzanian young infants hospitalized with ‘clinical severe infection’ as defined by WHO IMCI criteria. To meet
these goals, we propose to conduct a ‘gold standard’ randomized, double-blind, placebo-controlled trial of zinc
supplementation in Dar es Salaam, Tanzania.
Briefly, we will enroll 3,250 Tanzanian young infants (0-59 days) hospitalized with clinical severe infection in
Dar es Salaam, Tanzania. All young infants will receive standard antibiotic treatment and will be randomized to
receive a 14-day course of twice-daily oral 5 mg elemental zinc supplements (10 mg per day) or a matching 14-
day course of a twice-daily placebo regimen. Participants will be followed-up for 90 days to assess vital status
and treatment outcomes. We will also collect biological specimens to evaluate potential mechanisms of action
and assess modification of any treatment effect by etiology of infection. The primary outcomes of the trial are
i) 90-day all-cause mortality and ii) Treatment failure (composite endpoint of death, a new requirement for life
support or need to change to second-line antibiotics). The secondary outcomes of the trial include a) time to
cessation of signs and symptoms of clinical severe infection, b) time to hospital discharge, c) risk of re-
hospitalization and d) 90-day change in nutritional status as assessed by length-for-age, weight-for-length, and
weight-for-age z-scores.
Evidence from this randomized trial is urgently needed as low-cost and high-impact innovation to improve
young infant survival will be required for Tanzania and other developing countries to reach the child mortality
Sustainable Development Goal (SDG) by 2030.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Assessing the relationship between environmental enteric dysfunction and poor growth via a newly developed 11-plex assay
-
批准号:10021657
-
项目类别:
-
资助金额:$18.52万
-
财政年份:2019
-
负责人:CHRISTOPHER P DUGGAN
-
依托单位:
Patient-oriented Research in Pediatric Diarrheal Diseases
-
批准号:8680269
-
项目类别:
-
资助金额:$19.11万
-
财政年份:2010
-
负责人:CHRISTOPHER P DUGGAN
-
依托单位:
Patient-oriented Research in Pediatric Diarrheal Diseases
-
批准号:8294784
-
项目类别:
-
资助金额:$19.11万
-
财政年份:2010
-
负责人:CHRISTOPHER P DUGGAN
-
依托单位:
Patient-oriented Research in Pediatric Diarrheal Diseases
-
批准号:8471737
-
项目类别:
-
资助金额:$19.11万
-
财政年份:2010
-
负责人:CHRISTOPHER P DUGGAN
-
依托单位:
Patient-oriented Research in Pediatric Diarrheal Diseases
-
批准号:8113298
-
项目类别:
-
资助金额:$19.11万
-
财政年份:2010
-
负责人:CHRISTOPHER P DUGGAN
-
依托单位:
Patient-oriented Research in Pediatric Diarrheal Diseases
-
批准号:7892835
-
项目类别:
-
资助金额:$19.17万
-
财政年份:2010
-
负责人:CHRISTOPHER P DUGGAN
-
依托单位:
Patient-oriented Research in Pediatric Diarrheal Diseases
-
批准号:9115582
-
项目类别:
-
资助金额:$18.07万
-
财政年份:2008
-
负责人:CHRISTOPHER P DUGGAN
-
依托单位:
Randomized trial of vitamin B12 in pregnant Indian women
-
批准号:7231556
-
项目类别:
-
资助金额:$8.89万
-
财政年份:2007
-
负责人:CHRISTOPHER P DUGGAN
-
依托单位:
NUTRITION SUPPORT IN PEDIATRIC STEM CELL TRANSPLANTATION - A RCT
-
批准号:7607255
-
项目类别:
-
资助金额:$11.08万
-
财政年份:2007
-
负责人:CHRISTOPHER P DUGGAN
-
依托单位:
A Trial of Zinc and Micronutrients in Tanzanian Children
-
批准号:7270675
-
项目类别:
-
资助金额:$38.62万
-
财政年份:2006
-
负责人:CHRISTOPHER P DUGGAN
-
依托单位:
A Trial of Zinc and Micronutrients in Tanzanian Children
-
批准号:7647894
-
项目类别:
-
资助金额:$38.51万
-
财政年份:2006
-
负责人:CHRISTOPHER P DUGGAN
-
依托单位:
NUTRITION SUPPORT IN PEDIATRIC STEM CELL TRANSPLANTATION - A RCT
-
批准号:7380740
-
项目类别:
-
资助金额:$4.28万
-
财政年份:2006
-
负责人:CHRISTOPHER P DUGGAN
-
依托单位:
A Trial of Zinc and Micronutrients in Tanzanian Children
-
批准号:7885509
-
项目类别:
-
资助金额:$39.39万
-
财政年份:2006
-
负责人:CHRISTOPHER P DUGGAN
-
依托单位:
A Trial of Zinc and Micronutrients in Tanzanian Children
-
批准号:7477909
-
项目类别:
-
资助金额:$38.77万
-
财政年份:2006
-
负责人:CHRISTOPHER P DUGGAN
-
依托单位:
A Trial of Zinc and Micronutrients in Tanzanian Children
-
批准号:7034788
-
项目类别:
-
资助金额:$42.56万
-
财政年份:2006
-
负责人:CHRISTOPHER P DUGGAN
-
依托单位:
NUTRITION SUPPORT IN PEDIATRIC STEM CELL TRANSPLANTATION - A RCT
-
批准号:7204723
-
项目类别:
-
资助金额:$2.54万
-
财政年份:2005
-
负责人:CHRISTOPHER P DUGGAN
-
依托单位:
NUTRITIONAL ASSESSMENT AND INTERVENTIONS IN PEDIATRIC HIV
-
批准号:7204656
-
项目类别:
-
资助金额:$2.0万
-
财政年份:2005
-
负责人:CHRISTOPHER P DUGGAN
-
依托单位:
Arginine metabolism in cystic fibrosis patients. A stable isotope study.
-
批准号:6975120
-
项目类别:
-
资助金额:$0.02万
-
财政年份:2004
-
负责人:CHRISTOPHER P DUGGAN
-
依托单位:
Nutrition Support in Pediatric Stem Cell Transplantation - A Randomized, Control
-
批准号:6975199
-
项目类别:
-
资助金额:$0.04万
-
财政年份:2004
-
负责人:CHRISTOPHER P DUGGAN
-
依托单位:
NUTRITIONAL ASSESSMENT AND INTERVENTIONS IN PEDIATRIC HIV
-
批准号:6975105
-
项目类别:
-
资助金额:$3.66万
-
财政年份:2004
-
负责人:CHRISTOPHER P DUGGAN
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: